Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation
Category: 2021
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
20210624 Transgene TG4001.12 FPI EN
Transgene announces the success of its Capital Increase via a Private Placement
20210622 – Transgene – Pricing PR – ENG – V DEF website
Transgene Launches a Capital Increase via a Private Placement
Transgene – Launch CP – ENG – website
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
20210608 – IP Invir.IO ICI – EN
Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
210527 – Transgene BioInvent_BT001 IND_EN
Combined General Meeting of May 26, 2021
20210526 post AG EN
Transgene reports business update and end Q1 2021 financial position
20210427 – Transgene – Q1 Financial update EN
Transgene Announces Upcoming Investor Meetings
20210412 – Transgene investor agenda EN
